PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.17
0.5–0.75x AXSM's 1.57. Martin Whitman would question if short-term obligations are sufficiently covered.
1.17
0.75–0.9x AXSM's 1.51. Bill Ackman would recommend finding ways to boost near-cash assets or reduce short-term liabilities.
1.16
Cash Ratio 1.25–1.5x AXSM's 0.89. Bruce Berkowitz might see a strong liquidity buffer compared to the competitor.
-1238.62
Negative interest coverage while AXSM shows 20.02. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.